The role of ketoconazole in seborrheic dermatitis

Cutis

Volumn 80, Issue 4, 2007, Pages 359-363

  Borgers, Marcel ^a,b   Degreef, Hugo ^c   Vermeerbergen, Griet ^a  

^a Barrier Therapeutics NV   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; KETOCONAZOLE;

ARTICLE; DERMATOMYCOSIS; GEL; HUMAN; MALASSEZIA; MICROBIOLOGY; SEBORRHEIC DERMATITIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; DERMATITIS, SEBORRHEIC; DERMATOMYCOSES; GELS; HUMANS; KETOCONAZOLE; MALASSEZIA;

EID: 38849144733     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Gupta AK, Bluhm R. Seborrhoic dermatitis. J Eur Acad Dermatol Venereol. 2004;18:13-26.
2. Unna PG. Seborrheal eczema. J Cut Urin Dis. 1887;5: 449-459.
3. Saboutaud R. Les Maladies Desquamatives: Pityriasis et Alopécies Pelliculaires. Vol 2. Paris, France: Masson Editeur; 1904.
4. Malassez L. Note sur le champignon du pityriasis simple. Arch Physiol. 1874;1:451-459.
5. Kligman AM, McGinley KJ, Leyden JJ. Dandruff, its causes and treatment. In: Orfanos CE, ed. Haar und Haarkrankheiten. Stuttgart, Germany: Gustav Fisher Verslag; 1979:663-680.
6. Cunningham AC, Leeming JP, Ingham E, et al. Differentiation of three serovars of Malassezia furfur. J Appl Bacteriol. 1990;68:439-446.
7. Guillot J, Guého E. The diversity of Malassezia yeasts confirmed by rRNA sequence and nuclear DNA. Antonie Van Leeuwenhoek. 1995;67:297-314.
8. Sugita T, Takashima M, Shinoda T, et al. New yeast species, Malassezia dermatis, isolated from patients with atopic dermatitis. J Clin Microbiol. 2002;40:1363-1367.
9. Sugita T, Tajima M, Takashima M, et al. A new yeast, Malassezia yarruitoensis, isolated from a patient with seborrheoic dermatitis, and its distribution in patients and healthy subjects. Microbiol Immunol. 2004;48:579-583.
10. Cabanes FJ, Hernandez JJ, Castella G. Molecular analysis of Malassezia sympodialis - related strains from domestic animals. J Clin Microbiol. 2005;43:277-283.
11. Hirai A, Kano R, Makimura K, et al. Malassezia nana sp nov, a novel lipid-dependent yeast species isolator from animals. Int J Syst Evol Microbiol. 2004;54(pt 2):623-627.
12. Heeres J, Backx LJ, Mostmans JH, et al. Antimycotic imidazoles. part 4. synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J Med Chem. 1979;22:1003-1005.
13. Ford GP, Farr PM, Ive FA, et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol. 1984;111:603-607.
14. Skinner RB, Noah PW, Taylor RM, et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol. 1985;12(5 pt 1):852-856.
15. Ive FA. An overview of experience with ketoconazole shampoo. Br J Clin Pract. 1991;45:279-284.
16. Peter RM, Barthauer V. Successful treatment and profylaxis of scalp seborrheic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol. 1995;132:441-445.
17. Piérard GE, Piérard-Franchimont C, Van Cutsem J, et al. Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. Int J Dermatol. 1991;30:806-809.
18. Hammer KA, Carson CF, Riley TV. In vitro activities of ketoconazole, econazole, miconazole and Melaleuca alternifolia (tea tree) oil against Malassezia species. Antimicrob Agents Chemother. 2000;44:467-469.
19. Faergemann J, Ausma J, Borgers M. In vitro activity of R126638 and ketoconazole against Malassezia species. Acta Derm Venereol. 2006;86:312-315.
20. Faergemann J, Borgers M. The effect of ketoconazole and itraconazole on the filamentous form of Pityrosporum ovale. Acta Derm Venereol. 1990;70:172-176.
21. Odds F, Ausma J, Van Gerven F, et al. In vitro and in vivo activities of the novel azole antifungal agent r126638. Antimicrob Agents Chemother. 2004;48:388-391.
22. Van Cutsem J, Van Gerven F, Cauwenbergh G, et al. The anti-inflammatory effects of ketoconazole. a comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea pigs. J Am Acad Dermatol. 1991;25(2 pt 1):257-261.
23. Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by altered immune response to Malassezia yeast. Br J Dermatol. 1998;139:254-263.
24. Sohnle PG, Collins-Lech C. Activation of complement by Pityrosporum orbiculare. J Invest Dermatol. 1983;80:93-97.
25. Hay RJ, Graham-Brown RA. Dandruff and seborrhoeic dermatitis: causes and management. Clin Exp Dermatol. 1997;22:3-6.
26. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000;1: 75-80.
27. Beetens JR, Loots W, Somers Y, et al. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol. 1986;35:883-891.
28. De Pedrini P, Rapisarda R, Spano G. The effect of ketoconazole on sebum secretion in patients suffering from acne and seborrhoea. Int J Tissue React. 1988;10: 111-113.
29. Piérard GE, Ries G, Cauwenbergh G. New insight into the topical management of excessive sebum flow at the skin surface. Dermatology. 1998;196:126-129.
30. Data on file. Geel, Belgium: Barrier Therapeutics NV; 2006.
31. Aerts F, De Brabander M, van den Bossche H, et al. The activity of ketoconazole in mixed cultures of fungi and human fibroblasts. Mykosen. 1980;23:53-67.
32. Verfaille C, Bols L, Borgers M, et al. Analyse comparative de l'activité de 3 generations d'agents inhibiteurs du métabolisme de l'acide rétinoique dans des cultures de kératinocytes épidermiques humains normaux. Act Ingén Cut. 2006;4:288-291.
33. Degreef H, Heeres J, Borgers M. Antifungal azoles for skin disorders. Expert Opin Ther Patents. 2006;16:1235-1253.
34. Beger B, Highton A, Legendre R. The irritation potential of topical formulations containing ketoconazole 2% and desonide 0.05% alone and in combination [abstract]. J Am Acad Dermatol. 2005;52:61.
35. Beger B, Highton A, Barranco C, et al. A double-blind, randomized, vehicle-controlled, parallel group, multicenter study to assess the efficacy and safety of a topical gel product containing ketoconazole SP 2% in the treatment of seborrheic dermatitis [abstract]. J Am Acad Dermatol. 2005;52:122.